临床与病理杂志2017，Vol.37Issue(7)：1406-1411,6.DOI:10.3978/j.issn.2095-6959.2017.07.014
托伐普坦治疗乙肝肝硬化失代偿期稀释性低钠血症的效果
Effect of tolvaptan in treatment of diluted hyponatremia for patients with decompensated hepatitis B cirrhosis
摘要
Abstract
Objective: To observe and explore the clinical efficacy and safety of tolvaptan in treatment of decompensated hepatitis B cirrhosis induced diluted hyponatremia.Methods: Ninety-two cases of decompensated hepatitis B cirrhosis patients from May 2015 to October 2016 were enrolled in the study and were randomized into treatment group (47 cases) and control group (45 cases) according to the random number, patients in control group were treated with conventional therapy and spironolactone plus hydrochlorothiazide treatment, the treatment group received conventional therapy and tolvaptan treatment, 7 days for a treatment course, blood Na+ concentration, 24 h urine volume afler treatment for 3, 5, 7 d and variations of liver and renal function before and afler treatment of the two groups were compared; besides, adverse reactions were noted.Results: Afler treatment for 3, 5, 7 d,blood Na+ concentration and 24 h urine volume of treatment group were all significantly higher than the control group, the diflerences between groups with statistical signiflcance (P<0.05). Afler 7 d treatment, the liver function of the two groups were significantly improved compared with pretreatment (P<0.05), and no signiflcant variation in renal function. There were no signiflcant diflerences in liver and renal function between the two groups afler 7d treatment (P>0.05). Two groups with incidences of thirst (8.5% vs 6.7%), frequent micturition (2.1% vs 2.2%), dizziness (2.1% vs 4.4%) were similar (P>0.05). The treatment group had 1 case suspend medication for blood Na+ concentration and urine volume increased significantly afler 5 d treatment.Conclusion: Based on conventional therapy for decompensated hepatitis B cirrhosis induced dilution hyponatremia patients, tolvaptan added can significantly increase urine volume and blood Na+ concentration, and adverse drug reactions can be controllable关键词
失代偿期肝硬化/稀释性低钠血症/托伐普坦/水钠潴留/疗效Key words
decompensated cirrhosis/diluted hyponatremia/diluted hyponatremia/tolvaptan/water and sodium retention/clinical efficacy引用本文复制引用
王艳红,魏军,张雨..托伐普坦治疗乙肝肝硬化失代偿期稀释性低钠血症的效果[J].临床与病理杂志,2017,37(7):1406-1411,6.基金项目
秦皇岛市科技支撑计划项目(201502A155).This work was supported by Science and Technology Project of Qinhuangdao, China (201502A155). （201502A155）
